You are logged on as Guest.
RegisterLoginShopping cart (Empty)
 United States

DLL3 (human):Fc (human), (recombinant)

Notch ligand
 
ALX-201-422-C010 10 µg 353.00 USD
 
ALX-201-422-C050 50 µg 839.00 USD
 

Product Specification

Alternative Name:Delta-like protein 3 (human), Delta3
 
Endotoxin Content:<0.1EU/µg protein (LAL-test).
 
Purity:≥90% (SDS-PAGE)
 
Formulation:Lyophilized from a 0.2µm-filtered solution in PBS, pH 7.2.
 
Source/Host:Produced in HEK 293 cells. Signal peptide and extracellular domain of recombinant human DLL3 (aa 1-466) are fused at the C-terminus to the Fc portion of human IgG1.
 
Long Term Storage:-20°C
 
Use/Stability:Working aliquots are stable for up to 3 months when stored at -20°C.
 
Handling:After opening, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
 
Background / Technical Information:UniProt ID Q9NYJ7: DLL3 (human)
 
201-422
Figure: SDS-PAGE of DLL3 (human):Fc (human) (rec.) (Prod. No. ALX-201-422)
201-422 2 new
Figure 2: Adipogenesis inhibition of 3T3L-1 cells by DLL3 (human):Fc (human) (rec.) (Prod. No. ALX-201-422).
Method: 3T3L-1 cells were maintained in DMEM, supplemented with 10% fetal bovine serum and penicillin-streptomycin. For initiation of differentiation, 3T3L-1 cells were cultured in growth medium supplemented with 1μM Dexamethasone, 0.5mM IBMX and 10μg/ml insulin (day 0). The medium was changed every 2 days and staining with Oil Red O was typically performed on day 7. As negative control, human TNF-α (20ng/ml) was used. To immobilize Notch ligands in the culture plates, plates were incubated with a solution of DLL3 (human):Fc (human) (rec.) (5μg/ml) or hCD137(4-1BB)-Fc (5μg/ml).
Please mouse over
201-422 201-422 2 new

Related Literature

Product Flyers
Notch Ligands
Add to order list
Notch Ligands 08-Mar-10
Download as PDF

TOPIX Newsletters
TOPIX III/09 - Product Newsletter from Enzo Life Sciences
Add to order list
TOPIX III/09 - Product Newsletter from Enzo Life Sciences 06-Jul-09
Download as PDF

All new literature pieces

©2010 Enzo Life Sciences, Inc.,